Patient Advocacy

Catilena, living with hATTR amyloidosis

Alnylam Advocacy Imperatives

Actively listen to patients and integrate their perspectives across our business

Actively listen to patients and integrate their perspectives across our business

Engage, empower and inspire advocacy groups to meet the needs of patient communities

Engage, empower and inspire advocacy groups to meet the needs of patient communities

Support and partner on patient education and disease awareness programs

Support and partner on patient education and disease awareness programs

Patient Advocacy Around the World

Working in more than 20 countries with over 60 Patient Advocacy Groups (PAGs)

ADVOCACY GROUP LEGEND:

  Acute Hepatic Porphyria
  Hereditary ATTR Amyloidosis
  Primary Hyperoxaluria Type 1
map-pins

Patient Advocacy at Alnylam

Patient Advocacy at Alnylam
+ +
Patient Advocacy at Alnylam
+ +
Patient Advocacy at Alnylam
+ +

Patient Advocacy and Engagement Team

Meet the Patient Advocacy & Engagement Team

Greg Robertson

Senior Director,

Global Rare Diseases

Maidenhead, UK

FRAN KOCHMAN

Senior Director,

TTR/Amyloidosis

Cambridge, MA

Lena Geltenbort-Rost

Director,

TTR/Amyloidosis

International Region

AIKO MIURA

Associate Director,

Asia Pacific Region

Tokyo, Japan

Meet the Patient Advocacy & Engagement Team

Greg Robertson

Senior Director,

Global Rare Diseases

Maidenhead, UK

FRAN KOCHMAN

Senior Director,

TTR/Amyloidosis

Cambridge, MA

Lena Geltenbort-Rost

Director,

TTR/Amyloidosis

International Region

AIKO MIURA

Associate Director,

Asia Pacific Region

Tokyo, Japan

Additional Alnylam Resources

We are committed to supporting patients and their families throughout their journey with a wide range of programs and services—from diagnosis to access to treatment and care.

We offer a range of patient support services to help those impacted by diseases we are focused on.

Learn More ›

We believe that people who may benefit from our innovative medicines should be able to access them and this guides the actions we take as a company.

Learn More ›

Our medicines, based on RNA interference (RNAi), represent an innovative new approach to treating disease.

Learn More ›

Hereditary ATTR amyloidosis is a rare, inherited genetic disease caused featuring a wide variety of nervous system, cardiac, and digestive symptoms.

Learn More ›

In certain circumstances, we work with physicians to make our investigational therapies available to patients who might not be otherwise eligible for or have access to them.

Learn More ›

We are currently running several different clinical trials for diseases across multiple therapeutic areas.

Learn More ›

Acute hepatic porphyria (AHP) refers to a family of ultra-rare, genetic diseases characterized by potentially life-threatening attacks and, for some patients, chronic manifestations.

Learn More ›

Primary hyperoxaluria type 1 (PH1) is an ultra-rare genetic disease that leads to frequent kidney stones, progressive kidney disease, and multi-organ dysfunction.

Learn More ›

Get in touch with us at: patientadvocacy@alnylam.com

Understanding RNAi

RNA interference (RNAi) is the core discovery that forms the therapies Alnylam is developing. It is recognized as a major scientific breakthrough—but how does it work, exactly?

Learn About How RNAi-Based Medicines Work

Alnylam Patient Advocacy News

Visit the Alnylam Newsroom ›

FOLLOW US

Visit our social channels to learn more about the innovative work we are doing at Alnylam.